Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11973)	5/23/2013 11:27:21 AM
From: Mimbari	2 Recommendations Read Replies (2) \| Respond to of 13111

These past posts are some of the craziest things I have heard. Dosing: they know the dosing and there is no problem. PIII:number one goal is to get a working drug approved and not to make the study more difficult to reach end points. Stage four patients eliminated from Phase III study: that was done on the insistence of the FDA and not PVCT along with the decrease in number of patients needed. For those of you who think NTTG knows something you are just being fooled by big words and made up protocol. NTTG has never run a drug trial. Bystander effect: exactly that! The drug was never designed to cause that. That was a happy second effect observed. Sort of like when Pfizer developing a drug to raise cardiac pressure but found it had a second effect of giving you a tent pole, a big bonus. So now because there is an observed bystander effect it raises the awareness that your own immune system can help eradicate the disease. That observation deserves its own study (currently underway with Moffit) and does not need to be included in a phase III MM design. Bottom line is to get the drug approved because it is needed.